Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Common Equity data on record, last reported at $15.4 million in Q1 2025.

  • For Q1 2025, Common Equity rose 10.83% year-over-year to $15.4 million; the TTM value through Mar 2025 reached $15.4 million, up 10.83%, while the annual FY2025 figure was $15.4 million, 10.83% up from the prior year.
  • Common Equity reached $15.4 million in Q1 2025 per SXTC's latest filing, up from $13.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $16.1 million in Q1 2022 and bottomed at $13.9 million in Q1 2024.
  • Average Common Equity over 5 years is $15.2 million, with a median of $15.4 million recorded in 2025.
  • Peak YoY movement for Common Equity: surged 69.78% in 2021, then fell 8.65% in 2023.
  • A 5-year view of Common Equity shows it stood at $16.0 million in 2021, then grew by 0.76% to $16.1 million in 2022, then decreased by 8.65% to $14.7 million in 2023, then fell by 5.18% to $13.9 million in 2024, then rose by 10.83% to $15.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $15.4 million in Q1 2025, $13.9 million in Q1 2024, and $14.7 million in Q1 2023.